중추신경계 분야 제휴 및 라이선싱 계약(2020-2026년)

Central Nervous System (CNS) Collaboration and Licensing Deals 2020-2026

Understand the CNS partnering landscape using intelligence from 966 real-world collaboration and licensing deals.

Central Nervous System (CNS) Collaboration and Licensing Deals 2020-2026 provides comprehensive intelligence on 966 partnering deals involving CNS assets, technologies and development programs.

CNS partnering spans a diverse range of therapeutic indications, technologies and stages of development, with deal structures reflecting the scientific complexity, development risk and commercial potential of individual opportunities.

The report brings this activity together in one resource, enabling users to understand who is partnering, which CNS opportunities are attracting interest, how transactions are structured, what financial terms have been disclosed and how dealmaking differs across therapeutic indications, technologies and stages of development.

Rather than simply providing a list of transactions, the report combines market-wide deal analysis with financial benchmarking, leading dealmaker intelligence, detailed transaction records and access to publicly available contract documents where available.

It provides a practical intelligence and benchmarking resource for business development, licensing, search and evaluation, corporate strategy, R&D strategy, competitive intelligence and legal teams involved in CNS partnering.

Understand the CNS partnering landscape

The report analyzes CNS dealmaking from 2020 to 2026, including:

• Trends in CNS partnering by year
• Deal activity by deal type
• Industry sector
• Stage of development at the time of partnering
• Technology type
• CNS therapeutic indication
• Most active CNS dealmakers
• Leading deals by disclosed value
• How CNS partnering activity is evolving
• This enables users to identify where activity is concentrated and understand which companies, technologies, development stages and therapeutic areas are attracting partnering interest.
• Benchmark CNS deal financials
• Financial terms can vary considerably according to the CNS asset, development stage, technology, rights granted and overall transaction structure.

The report provides dedicated analysis of disclosed financial terms, including:

• Headline deal values
• Upfront payments
• Milestone payments
• Royalty rates
• Users can then investigate the individual transactions behind these benchmarks to understand the wider context surrounding the disclosed economics.
• This provides real-world reference points for internal benchmarking, opportunity assessment, deal preparation and negotiation.
• Financial benchmarks are most useful when interpreted alongside the structure and circumstances of comparable transactions rather than as standalone averages, and the report provides the underlying deal intelligence needed to establish that context.
• Identify leading CNS dealmakers and prospective partners
• The report identifies the most active companies in CNS partnering and provides extensive transaction histories that enable users to investigate their previous activity.

This can help users identify:

• Companies actively seeking CNS opportunities
• Prospective licensing and collaboration partners
• Organizations repeatedly partnering in particular CNS indications
• Companies active at relevant stages of development
• Dealmakers demonstrating interest in specific technologies or modalities
• Competitors pursuing similar external innovation strategies
• For companies seeking to partner a CNS asset or technology, previous transaction activity can provide valuable evidence of which organizations have demonstrated an appetite for comparable opportunities.
• Compare partnering activity across CNS indications
• CNS encompasses a broad range of distinct neurological, neurodegenerative and related therapeutic indications, each with its own development and partnering dynamics.
• The report analyzes deals by CNS therapeutic indication, allowing users to move beyond broad market-level benchmarks and focus on transactions most relevant to a particular program or strategic area.
• Combined with analysis by technology and development stage, this enables users to identify more meaningful comparable deals and prospective partners.
• Understand how CNS agreements are structured
• The report includes collaboration, licensing, development, research and other partnering transactions.

Depending on the transaction and available disclosure, users can investigate areas including:

• Rights granted and retained
• Research and development responsibilities
• Licensing rights
• Exclusivity
• Geographic rights
• Intellectual property
• Development and regulatory obligations
• Manufacturing and supply responsibilities
• Commercialization rights
• Financial consideration
• Milestones and royalties
• Governance
• Term and termination provisions
• These real-world examples provide useful reference points when considering the appropriate structure for a CNS partnership.
• Learn from real-world contract documents
• Where publicly available, the report provides access to underlying contract documents for selected CNS transactions.

These agreements can provide substantially more detail than headline announcements alone, enabling users to examine how companies have documented areas such as:

• Scope of rights
• Development obligations
• Intellectual property
• Exclusivity
• Financial terms
• Milestone triggers
• Royalty provisions
• Commercialization rights
• Termination and other negotiated provisions
• For teams preparing or negotiating a CNS collaboration or licensing agreement, access to real contract language provides valuable insight into how comparable deals have been structured in practice.
• Comprehensive CNS deal directory
• The report includes a comprehensive directory of 966 CNS collaboration and licensing deals, providing a detailed resource for identifying relevant precedent transactions.

Deals can be reviewed by:

• Company
• Technology type
• Therapeutic indication
• Contract availability
• Individual transactions are linked to their underlying deal records, providing a route to further deal information and associated contract documentation where available.
• Who should use this report?
• Business Development and Licensing teams
• Identify comparable CNS transactions, prospective partners and relevant deal structures.
• Search and Evaluation teams
• Understand which companies are actively seeking CNS opportunities across particular indications, technologies and development stages.
• Biotechnology Companies Seeking Partners
• Identify organizations with demonstrated interest in comparable CNS assets, technologies and development programs.
• Corporate and R&D Strategy teams
• Understand how competitors and prospective partners are building CNS pipelines through external innovation.
• Competitive and Market Intelligence teams
• Track partnering activity by company, indication, development stage and technology to understand evolving strategic priorities.
• Legal and Transaction teams
• Review publicly available contracts and precedent agreement structures to support transaction preparation and negotiation.
• Turn market-wide CNS intelligence into company-specific insight
• For qualifying customers, Current Partnering can also provide a Customized Executive Partnering Briefing alongside the report.
• The briefing applies the underlying CNS deal intelligence to the customer's own asset, technology, indication or partnering objectives.
• Depending on requirements, this can include relevant comparable transactions, prospective partners, competitor activity, development-stage analysis, deal structures, financial benchmarks, royalty analysis, contract insights and other intelligence selected specifically for the client's situation.
• Request a sample or contact Current Partnering to discuss the report and whether a customized analysis can be provided for your organization.

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in central nervous system dealmaking

• 2.1. Introduction
• 2.2. Central nervous system partnering over the years
• 2.3. Central nervous system partnering by deal type
• 2.4. Central nervous system partnering by industry sector
• 2.5. Central nervous system partnering by stage of development
• 2.6. Central nervous system partnering by technology type
• 2.7. Central nervous system partnering by therapeutic indication

Chapter 3 - Financial deal terms for central nervous system partnering

• 3.1. Introduction
• 3.2. Disclosed financials terms for central nervous system partnering
• 3.3. Central nervous system partnering headline values
• 3.4. Central nervous system deal upfront payments
• 3.5. Central nervous system deal milestone payments
• 3.6. Central nervous system royalty rates

Chapter 4 - Leading central nervous system deals and dealmakers

• 4.1. Introduction
• 4.2. Most active in central nervous system partnering
• 4.3. List of most active dealmakers in central nervous system
• 4.4. Top central nervous system deals by value

Chapter 5 - Central nervous system contract document directory

• 5.1. Introduction
• 5.2. Central nervous system partnering deals where contract document available

Chapter 6 - Central nervous system dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by central nervous system therapeutic target
• Deal Directory
• Deal Directory - Central nervous system deals by company A-Z
• Deal Directory - Central nervous system deals by technology type
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Central nervous system partnering since 2020
• Figure 2: Central nervous system partnering by deal type since 2020
• Figure 3: Central nervous system partnering by industry sector since 2020
• Figure 4: Central nervous system partnering by stage of development since 2020
• Figure 5: Central nervous system partnering by technology type since 2020
• Figure 6: Central nervous system partnering by indication since 2020
• Figure 7: Central nervous system deals with a headline value
• Figure 8: Central nervous system deals with upfront payment values
• Figure 9: Central nervous system deals with milestone payment
• Figure 10: Central nervous system deals with royalty rates
• Figure 11: Active central nervous system dealmaking activity since 2020
• Figure 12: Top central nervous system deals by value since 2020